Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

Posted by on Sep 27, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic sensitivity. Some...

Read More

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Posted by on Sep 18, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding venetoclax (Venclexta) to a dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) regimen as initial therapy in patients with aggressive B-cell lymphoma. The data showed that venetoclax with dose-adjusted EPOCH-R was effective...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More

Evaluating response to SARS-CoV-2 vaccination in patients with blood cancers

Evaluating response to SARS-CoV-2 vaccination in patients with blood cancers

Posted by on Aug 26, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate the rate of response (seroconversion) to SARS-Cov-2 vaccination in patients with blood cancers. This study concluded that seroconversion rates in these patients were significantly lower than that of healthy controls.   Some background The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)...

Read More

How effective is non-myeloablative chemotherapy after high-dose methotrexate-based treatment in patients with primary central nervous system lymphoma?

How effective is non-myeloablative chemotherapy after high-dose methotrexate-based treatment in patients with primary central nervous system lymphoma?

Posted by on Jun 1, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with primary central nervous system lymphoma (PCNSL) on high-dose methotrexate (HD-MTX; Otrexup)-based chemotherapy followed by non-myeloablative consolidation therapy. The study showed that HD-MTX-based chemotherapy with non-myeloablative consolidation therapy is an alternative and...

Read More

Evaluating COVID-19 vaccination in immunocompromised patients with blood cancers

Evaluating COVID-19 vaccination in immunocompromised patients with blood cancers

Posted by on May 31, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate if immunocompromised patients with blood cancers benefit from COVID-19 vaccination. This study concluded that these patients should not be excluded from COVID-19 vaccination.  Some background Patients with blood cancers are at high risk for severe forms of COVID-19 disease due to lower immune...

Read More

Evaluating the effectiveness of immunochemotherapy treatments for advanced stage follicular lymphoma.

Evaluating the effectiveness of immunochemotherapy treatments for advanced stage follicular lymphoma.

Posted by on May 31, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of common immuno-chemotherapy (ICT) treatments for advanced follicular lymphoma (FL) for front-line therapy. The study showed that obinutuzumab (Gazyva; G) combined with bendamustine (Treanda; Benda) (G-Benda-G regimen) had the best survival without cancer worsening in patients with advanced...

Read More

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Posted by on May 8, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data showed that pembrolizumab in combination with rituximab was safe and effective in these patients. Some background Follicular lymphoma (FL)...

Read More

Comparing the effectiveness and safety between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Comparing the effectiveness and safety between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Posted by on Apr 26, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and modified non-Hodgkin lymphoma (NHL) Berlin-Frankfurt-Münster-90 (NHL-BFM-90; cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, methotrexate, vindesine, dexamethasone, cytarabine)...

Read More

Comparing the risks of developing second primary cancers over time among survivors of non-Hodgkin lymphoma versus the general population.

Comparing the risks of developing second primary cancers over time among survivors of non-Hodgkin lymphoma versus the general population.

Posted by on Apr 10, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the risks of developing second primary cancers over time among survivors of non-Hodgkin lymphoma (NHL) versus the general population. The data showed that survivors of NHL had an increased risk of developing second primary cancers over time compared to the general population. Some background NHL is cancer that starts...

Read More

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Posted by on Apr 3, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of mosunetuzumab (RG7828) for the treatment of patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that mosunetuzumab resulted in long-lasting complete responses with manageable side effects for these patients. Some background NHL is cancer that...

Read More